Cargando…

A Phase I trial of talazoparib in patients with advanced hematologic malignancies

AIM: The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. PATIENTS & METHODS: This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy in advanced hematologic malignancies (coh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gopal, Ajay K, Popat, Rakesh, Mattison, Ryan J, Menne, Tobias, Bloor, Adrian, Gaymes, Terry, Khwaja, Asim, Juckett, Mark, Chen, Ying, Cotter, Matthew J, Mufti, Ghulam J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609999/ https://www.ncbi.nlm.nih.gov/pubmed/34840720 http://dx.doi.org/10.2217/ijh-2021-0004

Ejemplares similares

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
por: Gaymes, Terry J, et al.
Publicado: (2021)

Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies
por: Salih, Zena, et al.
Publicado: (2013)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

The mortality burden of hematological malignancies in Ecuador
por: Garrido, David, et al.
Publicado: (2021)

Ascorbic acid serum levels are reduced in patients with hematological malignancies
por: Huijskens, Mirelle J.A.J., et al.
Publicado: (2016)

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies
por: Kohl, Vanessa, et al.
Publicado: (2019)

Human metapneumovirus pneumonia in patients with hematological malignancies
por: Godet, Cendrine, et al.
Publicado: (2014)

Reactivation of hepatitis B virus infection in patients with hematologic disorders
por: Wang, Bo, et al.
Publicado: (2019)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma
por: Del Pozo, Vanessa, et al.
Publicado: (2021)

The Role of Vitamin D in Hematologic Disease and Stem Cell Transplantation
por: Hall, Aric C., et al.
Publicado: (2013)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2021)

Metagenomic Next-Generation Sequencing for Diagnostically Challenging Mucormycosis in Patients with Hematological Malignancies
por: Zhang, Meng, et al.
Publicado: (2022)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
por: Durairaj, Chandrasekar, et al.
Publicado: (2021)

Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
por: Schwarz, Florian, et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Galactomannan antigen detection using bronchial wash and bronchoalveolar lavage in patients with hematologic malignancies
por: Taremi, Mahnaz, et al.
Publicado: (2015)

Febrile neutropenia: significance of elaborated screening for respiratory viruses, and the comparison of different sampling methods, in neutropenic patients with hematological malignancies
por: Jansen, Rogier R, et al.
Publicado: (2013)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
por: Hoffman, Justin, et al.
Publicado: (2019)

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
por: Guo, Cen, et al.
Publicado: (2022)

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors
por: Luo, Yang, et al.
Publicado: (2023)

MicroRNAs in Myeloid Hematological Malignancies
por: Ciccone, Maria, et al.
Publicado: (2015)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

Molecular Testing in Hematologic Malignancies
por: Zitella, Laura J.
Publicado: (2022)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

HIV-associated hematologic malignancies: Experience from a Tertiary Cancer Center in India
por: Reddy, Rakesh, et al.
Publicado: (2016)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
por: Baldwin, Paige, et al.
Publicado: (2019)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours
por: Elmeliegy, Mohamed, et al.
Publicado: (2020)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b41llg15hc1lq97uarmh2qiv1i